{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001650664","name":"Editas Medicine, Inc.","summary":"Editas Medicine is a gene editing company developing CRISPR-based genomic medicines. Its platform includes CRISPR/Cas9 and CRISPR/Cas12a technologies targeting more than 95% of the human genome. Lead program EDIT-401 is an in vivo therapy targeting LDL-C reduction via LDLR upregulation for hyperlipidemia. The company also partners with Bristol Myers Squibb and Immatics for CAR T and cancer cell therapies, and licenses Cas9 technology to Vertex Pharmaceuticals.","people":[],"products":[{"name":"EDIT-401","type":"platform","description":"Experimental in vivo CRISPR-based therapy targeting noncoding LDLR gene region to upregulate LDLR expression and reduce LDL-C for heterozygous familial hypercholesterolemia."},{"name":"reni-cel (renizgamglogene autogedtemcel)","type":"platform","description":"Former experimental ex vivo gene-edited medicine for sickle cell disease and transfusion-dependent beta thalassemia; commercialization discontinued December 2024."},{"name":"CRISPR/Cas9 and CRISPR/Cas12a Gene Editing Platform","type":"platform","description":"Proprietary gene editing platform using natural and engineered variants of Cas9 and Cas12a enzymes with guide RNAs targeting over 95% of the human genome."},{"name":"Plug n Play LNP Platform","type":"platform","description":"Proprietary lipid nanoparticle delivery platform enabling targeted in vivo gene editing to liver, hematopoietic stem cells, and other extrahepatic tissues."}],"partnerships":[{"partner_name":"Bristol Myers Squibb / Juno Therapeutics","partnership_type":"development","description":"Collaboration advancing alpha-beta T-cell experimental medicines for solid tumors, liquid tumors, and autoimmune disease using Cas9 and AsCas12a; 14 programs including BMS CD19 HD Allo CAR T in Phase I.","start_date":null},{"partner_name":"Immatics","partnership_type":"development","description":"Non-exclusive collaboration and licensing agreement combining gamma-delta T cell adoptive cell therapies with gene editing for cancer treatment.","start_date":null},{"partner_name":"Vertex Pharmaceuticals","partnership_type":"licensing","description":"Non-exclusive license for Cas9 gene editing technology for ex vivo medicines targeting BCL11A in SCD and TDT, including CASGEVY; $50M upfront plus future fees.","start_date":null},{"partner_name":"DRI Healthcare Trust (DRI)","partnership_type":"strategic","description":"Agreement providing $57M upfront to DRI in exchange for purchasing up to 100% of certain future fixed and sales-based annual license fees from the Vertex License Agreement.","start_date":null},{"partner_name":"Unnamed LNP licensor","partnership_type":"licensing","description":"Collaboration and license agreement accessing liver-targeting LNPs to support in vivo upregulation of liver targets including LDLR for EDIT-401.","start_date":null},{"partner_name":"The Broad Institute / Harvard","partnership_type":"licensing","description":"Editas licenses Cas9 technology from Broad and Harvard and owes a mid-double-digit percentage of Vertex License Agreement payments related to this technology.","start_date":null}],"affiliations":[],"origin":{"leaf":"87cdf94217bca226eb723e66fc73465a682a93060a08ba4e867053068b3e95d6","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"a8672512f9cad291d5af2e28eeae0e44af0a15a743ade6821771e569cf13c1f7","parent":"96684b3f115ec9b5337fd6fb70d1b8d0e9d2ca04c5ae1b257ffa66377df62ea9","source":"0001650664-26-000017","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":443,"hourly_limit":500,"remaining":57,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}